OncoMatch/Clinical Trials/NCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Is NCT05830500 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Anlotinib Hydrochloride Capsule for medullary thyroid cancer.
Treatment: Anlotinib Hydrochloride Capsule — This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: VEGFR inhibitor (anlotinib, vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib)
Patients who have previously used anlotinib hydrochloride capsules or similar Vascular Endothelial Growth Factor- Tyrosine Kinase Inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib, etc.;
Lab requirements
Blood counts
Hemoglobin ≥85g/L; ANC ≥1.5×10^9/L; Platelet ≥80×10^9/L (no transfusion within 14 days)
Kidney function
Serum creatinine ≤1.5x ULN or Creatinine clearance rate ≥60 ml/min
Liver function
Total bilirubin (TBIL) ≤1.5x ULN; ALT and AST ≤2.5x ULN; if liver metastasis, ALT and AST ≤5x ULN
Major organ functions meet the following criteria within 7 days prior to the treatment: ... Blood routine examination ... Hemoglobin (Hb) ≥85g/L; Absolute Neutrophil Count (ANC) ≥1.5×10^9/L; Platelet (PLT) ≥80×10^9/L; ... Biochemical examination ... Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); Alanine transferase (ALT) and Aspartate transferase (AST) ≤2.5×ULN; If accompanied by liver metastasis, ALT and AST ≤5×ULN; Serum creatinine (Cr) ≤1.5×ULN or Creatinine clearance rate (CCr) ≥60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05830500 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGFR inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify